Axonics Inc
NASDAQ:AXNX

Watchlist Manager
Axonics Inc Logo
Axonics Inc
NASDAQ:AXNX
Watchlist
Price: 70.98 USD 0.75%
Market Cap: 3.6B USD
Have any thoughts about
Axonics Inc?
Write Note

Net Margin
Axonics Inc

-1.3%
Current
-20%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1.3%
=
Net Income
-5.7m
/
Revenue
431.9m

Net Margin Across Competitors

Country US
Market Cap 3.6B USD
Net Margin
-1%
Country US
Market Cap 200.4B USD
Net Margin
14%
Country US
Market Cap 191.7B USD
Net Margin
29%
Country US
Market Cap 141.1B USD
Net Margin
16%
Country US
Market Cap 134.3B USD
Net Margin
11%
Country IE
Market Cap 104.7B USD
Net Margin
13%
Country US
Market Cap 66.2B USD
Net Margin
9%
Country DE
Market Cap 58.1B EUR
Net Margin
8%
Country US
Market Cap 44.4B USD
Net Margin
74%
Country CN
Market Cap 308.3B CNY
Net Margin
33%
Country US
Market Cap 36.5B USD
Net Margin
9%
No Stocks Found

Axonics Inc
Glance View

Market Cap
3.6B USD
Industry
Health Care
Economic Moat
Narrow

Axonics Inc., a prominent player in the medical technology landscape, has carved a niche for itself by focusing diligently on the development and commercialization of innovative solutions for bladder and bowel dysfunction. Founded in 2012, the company's primary product is its Sacral Neuromodulation (SNM) system, designed to treat urinary and fecal incontinence. What differentiates Axonics is its dedication to addressing a pervasive issue with an underpinning focus on patient-centric design and effective long-term treatment. Its SNM system offers users rechargeable batteries, providing a less invasive and more cost-effective solution compared to traditional systems. This technology not only addresses significant medical needs but also aligns well with a growing trend toward minimally invasive solutions in medtech. The operational model of Axonics is straightforward yet well-suited to drive profitability. Revenues primarily derive from the sales of its SNM system, which is marketed directly to healthcare providers and practitioners. This involves an intricate network of sales representatives and a hands-on approach to training medical professionals on the benefits and use of their systems, ensuring that the technology translates efficiently into patient treatment. By focusing extensively on a specific segment within the broader medical device industry, Axonics has positioned itself to capitalize on a substantial market opportunity, driven by an aging population and increasing rates of incontinence-related conditions. This strategic approach not only underscores its commitment to delivering effective healthcare solutions but also signifies its potential for sustained growth within a competitive landscape.

AXNX Intrinsic Value
33.87 USD
Overvaluation 52%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1.3%
=
Net Income
-5.7m
/
Revenue
431.9m
What is the Net Margin of Axonics Inc?

Based on Axonics Inc's most recent financial statements, the company has Net Margin of -1.3%.